The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories.
The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process …

The 2013–2015 West African epidemic of Ebola virus disease (EVD) reminds us of how little
is known about biosafety level 4 viruses. Like Ebola virus, Lassa virus (LASV) can cause …

Antimalarial drugs have thus far been chiefly derived from two sources—natural products
and synthetic drug-like compounds. Here we investigate whether antimalarial agents with …

Chemogenetic characterization through in vitro evolution combined with whole-genome
analysis can identify antimalarial drug targets and drug-resistance genes. We performed a …

INTRODUCTION Malaria remains a devastating disease, affecting 216 million people annually,
with 445,000 deaths occurring primarily in children under 5 years old. Malaria treatment …

Microbial resistance to chemotherapy has caused countless deaths where malaria is
endemic. Chemotherapy may fail either due to pre-existing resistance or evolution of drug-resistant …

Identifying how small molecules act to kill malaria parasites can lead to new “chemically
validated” targets. By pressuring Plasmodium falciparum asexual blood stage parasites with …

Through rapid genetic adaptation and natural selection, the Plasmodium falciparum parasite—the
deadliest of those that cause malaria—is able to develop resistance to antimalarial …

Using parasite genotyping tools, we screened patients with mild uncomplicated malaria
seeking treatment at a clinic in Thiès, Senegal, from 2006 to 2011. We identified a growing …

The emergence of drug resistance is a major limitation of current antimalarials. The discovery
of new druggable targets and pathways including those that are critical for multiple life …